This health education program aims to help patients living with COPD experience better health outcomes and improved quality of life for the duration of their lives.

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Sanofi said this morning that its pipeline ... IL-33 inhibitor itepekimab for chronic obstructive pulmonary disease (COPD), and vaccines against acne, extra-intestinal pathogenic Escherichia ...

France’s Sanofi – a major player in the rare disease ... AATD is an inherited disorder whose primary consequence is life-threatening pulmonary emphysema, resulting in irreversible destruction ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

Binance, the world’s largest cryptocurrency exchange, has received a USD 2 billion investment from Abu Dhabi-based technology ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO ...